和元生物2年1期亏 2022年上市募13.23亿国泰海通保荐

Group 1 - The company reported a revenue of 120 million yuan in the first half of 2025, representing a year-on-year increase of 6.01% [1] - The net profit attributable to shareholders was -105 million yuan, an improvement from -113 million yuan in the same period last year [1] - The net cash flow from operating activities was -88.5 million yuan, compared to -115 million yuan in the previous year [1] Group 2 - In 2024, the company achieved a revenue of 248 million yuan, marking a year-on-year growth of 21.16% [2][3] - The net profit attributable to shareholders for 2024 was -322 million yuan, worsening from -128 million yuan in the previous year [2][3] - The net cash flow from operating activities was -61 million yuan, an improvement from -90 million yuan in the previous year [2][3] Group 3 - The company was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on March 22, 2022, with an initial public offering of 100 million shares at a price of 13.23 yuan [3] - The total amount raised from the IPO was 1.323 billion yuan, with a net amount of 1.197 billion yuan after expenses [4] - The company announced a capital increase of 0.3 shares for every share held, resulting in a total share capital of 641.15 million shares after the distribution [5]